Beijing Signals Tighter Grip on AI and Solar Exports

A Policy Shift Years in the Making

Chinese regulators unveiled a proposal on Friday, 16 October 2026, to expand the nation's export control framework, bringing artificial intelligence, biopharmaceutical technologies, and photovoltaic systems under formal restrictions. The move follows more than three years of escalating technology competition between Beijing and Western capitals, and signals a strategic pivot towards guarding domestic innovation advantages.

The proposal, issued by Chinese authorities, frames the expansion as necessary to prevent certain capabilities from "proliferating inappropriately". While the announcement did not specify which AI models, drug development techniques, or solar manufacturing processes would face restrictions, the breadth of the categories suggests regulators are casting a wide net across sectors where China has built considerable expertise.

At Opentechwire, we've tracked the gradual tightening of export controls across Asia's largest economies since 2022, when semiconductor restrictions became a primary tool of industrial policy. This latest draft extends that logic into fields where China holds either cost advantages (solar panels), growing research depth (biopharmaceuticals), or ambitions for global leadership (artificial intelligence).

The AI Dimension

Artificial intelligence sits at the centre of the proposal, reflecting both the technology's dual-use nature and Beijing's concerns about maintaining competitiveness. China's AI sector has matured rapidly over the past five years, with firms like DeepSeek, SenseTime, and iFlytek building large language models, computer vision platforms, and voice synthesis tools that rival Western counterparts in certain benchmarks.

Export controls on AI could cover several layers: pre-trained foundation models, fine-tuning datasets with sensitive characteristics (biometric, demographic, or behavioural), inference hardware optimised for specific workloads, or even algorithmic techniques for training efficiency. The lack of technical detail in the initial proposal leaves the scope open to interpretation, but the intent is clear. Beijing aims to retain control over how its AI capabilities diffuse beyond its borders.

This mirrors, in reverse, the export licensing requirements the United States imposed on advanced graphics processing units (GPUs) destined for China in 2022 and 2023. Both sides now operate under the assumption that AI superiority translates into economic and strategic advantage, and both are willing to fragment global supply chains to protect perceived leads.

Solar and Biopharmaceuticals Join the List

The inclusion of photovoltaic technology is particularly notable. China dominates global solar panel manufacturing, controlling an estimated 80 per cent of polysilicon production and a similar share of module assembly. Restricting exports of certain solar technologies could be aimed at preserving next-generation efficiency gains (such as tandem perovskite-silicon cells or advanced inverter control algorithms) that have not yet reached mass production overseas.

For foreign developers and project financiers, the practical impact will depend on whether the controls target manufacturing equipment, intellectual property, or finished products. If Beijing restricts the export of production lines or fabrication know-how, it could slow the diversification of solar supply chains that governments in Europe, North America, and India have been pursuing through subsidies and localisation mandates.

Biopharmaceutical controls are less straightforward to interpret. China has invested heavily in biologics manufacturing, gene therapy platforms, and contract research organisations (CROs) that serve global pharmaceutical companies. Export restrictions could apply to proprietary cell lines, novel drug delivery mechanisms, or data from clinical trials conducted in China. This would complicate partnerships between Chinese CROs and Western drugmakers, potentially forcing the latter to duplicate research infrastructure or accept delays in drug development timelines.

Regulatory Mechanics and Industry Uncertainty

The proposal is expected to undergo a public consultation period before formal adoption, a process that typically lasts 30 to 60 days in China's regulatory system. During this window, affected industries can submit comments, though the degree to which those inputs shape final rules varies.

For companies operating in or with China, the uncertainty lies in the classification criteria. Export controls in most jurisdictions rely on technical parameters: processing speed, accuracy thresholds, energy density, or biological specificity. Without published thresholds, firms cannot yet determine whether their products or services fall within the restricted categories.

Legal advisers in Hong Kong and Shanghai have begun preparing compliance frameworks that assume a broad interpretation. This includes auditing customer lists, segmenting product lines by capability, and establishing separate legal entities for domestic and international operations. The administrative burden is significant, particularly for startups and mid-sized firms that lack the compliance teams of state-owned enterprises or multinational corporations.

Geopolitical Context and Reciprocal Measures

The timing of the proposal aligns with ongoing friction over semiconductor access, rare earth exports, and dual-use technologies. In recent months, the United States has expanded its "entity list" to include additional Chinese AI firms, while the European Union has launched investigations into Chinese subsidies for electric vehicle batteries and solar panels.

China's response has been incremental but consistent: export bans on gallium and germanium in 2023, restrictions on graphite in early 2024, and now this draft covering higher-value technologies. Each measure is framed domestically as defensive, a reaction to what Beijing describes as efforts to "contain" its technological development.

From a supply chain perspective, the risk is fragmentation. If both blocs impose overlapping but non-identical restrictions, companies face the prospect of maintaining parallel R&D programmes, duplicating manufacturing, and navigating conflicting compliance regimes. This raises costs, lengthens development cycles, and reduces the efficiency gains that made globalised technology markets attractive in the first place.

What Comes Next

Once the consultation period closes, Chinese ministries will likely publish a detailed catalogue of controlled items, accompanied by licensing procedures. Firms seeking to export covered technologies will need to apply for permits, a process that can take weeks or months depending on the sensitivity of the application and the destination country.

For foreign buyers, the calculus shifts. If a critical input, whether an AI model, a biologic, or a solar component, becomes subject to Chinese export approval, procurement strategies must account for the possibility of denial or delay. This accelerates the push towards supply chain redundancy, a trend already visible in semiconductors and now spreading into adjacent sectors.

The proposal also sets a precedent for other nations. If China successfully restricts AI exports without triggering significant economic backlash, other countries with technology advantages may follow suit. South Korea's dominance in memory chips, Japan's leadership in semiconductor materials, and Taiwan's centrality in foundry services all become potential levers in future disputes.

At Opentechwire, we see this as another iteration of the same logic that has governed technology policy since 2022: control over critical capabilities is increasingly viewed as a national security imperative, and trade is no longer assumed to be neutral. The question is not whether other governments will adopt similar measures, but when, and how broadly they will define "critical".

The consultation period will reveal how Chinese industry responds, and whether Beijing is willing to narrow the scope in response to domestic pressure. For now, the message is clear: technologies that were once freely traded are being reclassified as strategic assets, and the era of unfettered technology exports is closing.